Latest Developments in Global Hepatic Antiviral Drugs Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Hepatic Antiviral Drugs Market

  • Pharmaceutical
  • Upcoming Report
  • Jan 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In December 2021, Pfizer had received the emergency use authorization from U.S. Food and (FDA) for Novel COVID-19 oral antiviral drug named PAXLOVID. PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is approved for emergency use in high-risk adults and children 12 years and older who weigh at least 40 kg
  • In December 2021, Cipla Limited had received the Emergency Use Authorization (EUA) permission by Drug Controller General of India (DCGI) for the launch of oral anti-viral COVID drug named Molnupiravir. Molnupiravir is the first oral antiviral to be authorized by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 infection in people who are at high risk of developing severe disease

Frequently Asked Questions